Скачать или смотреть “Librela for Dogs, Solensia for Cats — Are the Risks Worth the Benefit?”

This video summarizes public safety information about Librela (bedinvetmab) for dogs and Solensia (frunevetmab) for cats through October 22, 2025. It is informational only and not veterinary advice. Adverse event reports are spontaneous submissions and do not by themselves prove causation. Please consult your veterinarian about treatment decisions.
Primary sources used
FDA — “Dear Veterinarian” letter / Librela adverse event review.
U.S. Food and Drug Administration
FDA — Solensia ADE summary (1/13/2022–6/30/2025).
U.S. Food and Drug Administration
Zoetis — Librela Prescribing Information (safety section).
Zoetis
Zoetis — Solensia Prescribing Information / FAQ.
Zoetis
Selected peer-reviewed analyses (2025) on post-marketing reports.
Frontiers

(I included the October 22, 2025 cutoff).
Emphasize reports vs causation repeatedly — this is the key legal/factual safeguard.
U.S. Food and Drug Administration
Include the disclaimer “not veterinary advice” both visually and in the spoken script.
If you quote numbers (e.g., ADE counts or company claim like “fewer than 10 in 10,000”), cite the specific document and the exact date of that document.

Date of FDA “Dear Veterinarian” letter for Librela
The FDA issued the “Dear Veterinarian Letter” notifying veterinarians about adverse events in dogs treated with Librela on December 16, 2024

📚 Sources & Document Dates
Regulatory and official documents:
FDA “Dear Veterinarian” Letter – Librela (bedinvetmab): December 16, 2024
FDA / Zoetis Statement
FDA Adverse Drug Event (ADE) Report – Librela
• Period: May 5 2023 – March 31 2024 — Document dated April 1 2024
• Period: May 5 2023 – December 31 2024 — Document dated January 23 2025
FDA ADE Librela Reports
FDA Adverse Drug Event (ADE) Report – Solensia (frunevetmab)
• Period: January 13 2022 – March 31 2025 — Document dated April 11 2025
• Period: January 13 2022 – June 30 2025 — Document dated July 16 2025
FDA ADE Solensia Reports
Manufacturer information:
Zoetis Librela Prescribing Information (updated 2024): safety section lists most common reactions (urinary tract infection, skin infection, increased liver enzymes).
Zoetis Solensia Prescribing Information (updated 2024): safety section lists vomiting, diarrhea, and injection-site reactions as the most common adverse events.
Independent analyses:
2025 peer-reviewed pharmacovigilance and surveillance papers examining post-marketing reports of bedinvetmab and frunevetmab (Frontiers in Veterinary Science, 2025).

⚠️ Disclaimer:
This video summarizes publicly available regulatory and scientific data about Librela (bedinvetmab) and Solensia (frunevetmab) as of October 22 2025. It is for informational and educational purposes only and not veterinary medical advice. Adverse event reports are spontaneous submissions and do not prove causation. Always consult a licensed veterinarian regarding diagnosis or treatment decisions.